Ascendis Pharma A/S (ASND) |
|
91.09 -0.38 (-0.42%)
|
06-26 23:20 |
|
Open: |
92.67 |
Pre. Close: |
91.47 |
|
High:
|
93.89 |
Low:
|
86.23 |
|
Volume:
|
785,095 |
Market Cap:
|
5,083(M) |
|
|
|
|
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
93.94 - 94.42 |
94.42 - 94.79 |
|
Low:
|
85.18 - 85.65 |
85.65 - 86.02 |
|
Close:
|
90.31 - 91.14 |
91.14 - 91.77 |
|
Technical analysis |
as of: 2022-06-24 4:38:07 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 114.59 One year: 133.84 |
| Support: |
Support1: 85.23 Support2: 77.27 |
| Resistance: |
Resistance1: 98.11 Resistance2: 114.59 |
| Pivot: |
85.3  |
| Moving Average: |
MA(5): 87.54 MA(20): 85.36
MA(100): 101.93  MA(250): 124.45 |
| MACD: |
MACD(12,26): -0.8 Signal(9): -2 |
| Stochastic oscillator: |
%K(14,3): 78.2 %D(3): 67.2 |
| RSI: |
RSI(14): 55.7 |
| 52-week: |
High: 178.71 Low: 61.57 |
| Average Vol(K): |
3-Month: 521 (K) 10-Days: 362 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ASND ] has closed below upper band by 12.9%. Bollinger Bands are 22.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Sun, 26 Jun 2022
Ascendis Pharma A/S (NASDAQ:ASND) Stock Price Down 2% - Defense World
Tue, 14 Jun 2022
Ascendant Resources Announces Discovery of New Copper-Gold Zone and Reports Additional Strong Results From Its Infill Campaign at Lagoa Salgada, Portugal - Junior Mining Network
Fri, 10 Jun 2022
Here's Why Ascendis Pharma (NASDAQ:ASND) Can Manage Its Debt Despite Losing Money - Simply Wall St
Wed, 25 May 2022
Ascendant Resources Acquires 50% Ownership of Lagoa Salgada VMS Project, Portugal - GuruFocus.com
Mon, 23 May 2022
Should Biotechnology Stock Ascendis Pharma A/S (ASND) Be in Your Portfolio Monday? - InvestorsObserver
Thu, 12 May 2022
Why Ascendis Pharma Stock Is Sinking Today - The Motley Fool
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
57 (M) |
|
% Held by Insiders
|
4.417e+007 (%) |
|
% Held by Institutions
|
0 (%) |
|
Shares Short
|
6,320 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-4.4781e+008 |
|
EPS Est Next Qtl
|
0.01 |
|
EPS Est This Year
|
-0.15 |
|
EPS Est Next Year
|
0.14 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-5 |
|
Return on Assets (ttm)
|
808.5 |
|
Return on Equity (ttm)
|
-27.4 |
|
Qtrly Rev. Growth
|
7.78e+006 |
|
Gross Profit (p.s.)
|
1132.36 |
|
Sales Per Share
|
-61.87 |
|
EBITDA (p.s.)
|
5.90278e+006 |
|
Qtrly Earnings Growth
|
-8.8 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-418 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
7.7 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-1.48 |
|
Price to Cash Flow
|
3.75 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
5.76e+006 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
